INmune Bio, Inc.
INmune Bio, Inc. (INMB) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
inmb · stock forecast · 9 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$22.00
Consensus
$22.00
+1674.2% upside
Low
$22.00
Median: $22 · Last Close: $1.24
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.19 | ↓ 3.75% |
1-day model range: $1.17–$1.22. Peak: $1.22 (-3.75%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · INMB · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-11 | LUCID CAPITAL MARKETS | Upgrade ↑ | Neutral→Buy |
| 2025-07-02 | Maxim Group | Maintains | Buy→Buy |
| 2025-07-01 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2025-07-01 | Scotiabank | Downgrade ↓ | Sector Outperform→Sector Underperform |
| 2025-02-13 | Maxim Group | Maintains | Buy→Buy |
| 2025-02-11 | Scotiabank | Maintains | Sector Outperform→Sector Outperform |
| 2023-06-01 | Baird | Maintains | Outperform→Outperform |
| 2022-05-24 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2022-05-24 | BTIG | Maintains | Buy→Buy |
| 2022-01-24 | B. Riley Securities | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on INmune Bio, Inc. (INMB) stock. Of the recent 22 rating actions, 1 were upgrades and 3 were downgrades. 9 analysts currently cover INMB.
Analyst Recommendation Trends
INMB analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 99.5% YoY
Revenue Next Year
$6M
↑ 4670.0% YoY
EPS This Year
$-0.70
EPS Next Year
$-0.76
↑ 7.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast INMB EPS of $-0.70 for the current fiscal year, based on estimates from 2 analysts. The INMB revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The INMB stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus INMB price target is $22.00 (+1674.2% upside), with an analyst consensus of Buy.
The INMB short-term stock prediction for tomorrow is $1.19 (-3.75%).
INmune Bio, Inc. trades on NASDAQ under the ticker INMB. The INMB stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
INMB forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month INMB price target is $22.00, with a high forecast of $22.00 and a low of $22.00. The median price target is shown in the chart above when available. This implies +1674.2% potential upside from the current price of $1.24.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.